PRECISION - Non-Interventional Study
Research type
Research Study
Full title
PRECISION – A prospective observational study to assess the real-world effectiveness and tolerability of Latanoprost/Netarsudil fixed dose combination in reducing intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension
IRAS ID
369113
Contact name
Jonathan Clarke
Contact email
Sponsor organisation
Santen UK
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
0 years, 7 months, 9 days
Research summary
Glaucoma affects approximately 2% of adults aged 40 and over in the United Kingdom (UK) and is a leading cause of blindness. Ocular Hypertension (OHT) is high intraocular pressure (IOP) without optic nerve damage or vision loss and although not a direct cause of blindness, is the biggest risk factor for glaucoma, which damages the optic nerve, resulting in permanent vision loss over time if untreated.
Roclanda® is an ophthalmic solution already licensed (approved by the UK Medicines and Healthcare products Regulatory Agency - MHRA) and NICE (National Institute for Health and Care Excellence) and used to lower IOP for adults with Primary-Open Angle Glaucoma (POAG) or OHT. It contains a fixed dose of two medicines, Latanoprost and
Netarsudil (LAT/NET FDC), which work together to increase the drainage of fluid from the eye and help prevent damage to sight caused by high eye pressure.Large clinical trials have demonstrated that Roclanda® is effective at reducing IOP, and this study will be conducted to observe how well and how safely this medicine works in a real-world UK National Health Service (NHS) clinical setting. Eligible adult patients diagnosed with POAG or OHT, who have been prescribed LAT/NET FDC as part of their usual care, will be identified and enrolled from participating secondary care NHS hospital sites.
REC name
London - Queen Square Research Ethics Committee
REC reference
26/PR/0246
Date of REC Opinion
16 Mar 2026
REC opinion
Favourable Opinion